Literature DB >> 7780988

Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma.

M D Coltrera1, J Wang, P L Porter, A M Gown.   

Abstract

Breast carcinomas are known to express platelet-derived growth factor (PDGF), a known connective tissue mitogen. In order to further evaluate the potential role of PDGF in these epithelial tumors, expression of the PDGF B chain (PDGF-B) and the PDGF receptor beta subunit (PDGFR) was analyzed by immunocytochemistry and in situ hybridization in 49 benign and malignant breast tissues. PDGF-B expression was analyzed with respect to the expression of the proliferating cell nuclear antigen, as well as tumor grade, p53 overexpression, estrogen receptor, progesterone receptor, and c-erbB-2 expression. Expression of PDGF-B protein and mRNA was restricted to the breast epithelium and tumor cells except for scattered tissue macrophages. A strong correlation was found between increasing proliferating cell nuclear antigen indices and PDGF-B expression in both nonmalignant (P = 0.01) and malignant (P = 0.02) breast specimens. Decreased PDGF-B expression was found in postmenopausal atrophic breast tissue compared with normal breast tissue (P = 0.04). Within the subgroup of malignant tumors, no correlations were found between PDGF-B expression and tumor grade or p53 overexpression. In 16 of the malignant tumors evaluated for estrogen/progesterone receptor status and c-erbB-2 overexpression, no correlations with PDGF-B expression were found. Membranous PDGFR immunostaining was present within the fibroblastic cell population in all of the tissues examined but not in the nonmalignant breast epithelium. Six malignant specimens had detectable cytoplasmic expression of PDGFR. There was no correlation between this PDGFR expression and proliferating cell nuclear antigen indices, but a correlation was noted between increasing estrogen receptor expression and PDGFR cytoplasmic expression (P = 0.04). The results support a paracrine role for PDGF-B in malignant and benign breast epithelial cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780988

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

2.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

3.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase.

Authors:  D G Farwell; K A Shera; J I Koop; G A Bonnet; C P Matthews; G W Reuther; M D Coltrera; J K McDougall; A J Klingelhutz
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.

Authors:  Jieqiong Liu; Shan Liao; Yuhui Huang; Rekha Samuel; Tony Shi; Kamila Naxerova; Peigen Huang; Walid Kamoun; Rakesh K Jain; Dai Fukumura; Lei Xu
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

5.  Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity.

Authors:  S Maudsley; A M Zamah; N Rahman; J T Blitzer; L M Luttrell; R J Lefkowitz; R A Hall
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

6.  Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.

Authors:  M Skobe; N E Fusenig
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Authors:  Helen K Chew; William E Barlow; Kathy Albain; Danika Lew; Allen Gown; Daniel F Hayes; Julie Gralow; Gabriel N Hortobagyi; Robert Livingston
Journal:  Clin Breast Cancer       Date:  2008-12       Impact factor: 3.225

8.  An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Authors:  Alyssa Bottrell; Yong Hong Meng; Abdo J Najy; Newton Hurst; Seongho Kim; Chong Jai Kim; Eun-Sook Kim; Aree Moon; Eun Joo Kim; So Yeon Park; Hyeong-Reh Choi Kim
Journal:  Growth Factors       Date:  2019-09-23       Impact factor: 2.511

9.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.

Authors:  Janna Paulsson; Tobias Sjöblom; Patrick Micke; Fredrik Pontén; Göran Landberg; Carl-Henrik Heldin; Jonas Bergh; Donal J Brennan; Karin Jirström; Arne Ostman
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

10.  A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression.

Authors:  Carolyn V Ustach; Marcus E Taube; Newton J Hurst; Sunita Bhagat; R Daniel Bonfil; Michael L Cher; Lucia Schuger; Hyeong-Reh Choi Kim
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.